256 related articles for article (PubMed ID: 32862831)
1. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
3. KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer.
Ma SY; Wei P; Qu F
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4629-4641. PubMed ID: 31210304
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
5. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
Yao N; Sun JQ; Yu L; Ma L; Guo BQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
[TBL] [Abstract][Full Text] [Related]
6. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2.
He WP; Guo YY; Yang GP; Lai HL; Sun TT; Zhang ZW; Ouyang LL; Zheng Y; Tian LM; Li XH; You ZS; Xie D; Yang GF
Int J Med Sci; 2020; 17(15):2387-2395. PubMed ID: 32922205
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
8. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
Qiu JJ; Lin XJ; Tang XY; Zheng TT; Zhang XY; Hua KQ
Int J Cancer; 2020 May; 146(9):2588-2598. PubMed ID: 31577838
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
12. The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression.
Liu Y; Zong ZH; Guan X; Wang LL; Zhao Y
Gene; 2017 Oct; 633():42-47. PubMed ID: 28864116
[TBL] [Abstract][Full Text] [Related]
13. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
[TBL] [Abstract][Full Text] [Related]
14. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
15. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
16. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
17. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
Gao C; Yao H; Liu H; Feng Y; Yang Z
BMC Cancer; 2019 Mar; 19(1):237. PubMed ID: 30876464
[TBL] [Abstract][Full Text] [Related]
18. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer.
Zhang L; Chen H; Ding B; Jiang W
J Ovarian Res; 2022 Feb; 15(1):19. PubMed ID: 35105347
[TBL] [Abstract][Full Text] [Related]
19. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
20. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]